The side effects of Ostarine are limited as it appears to be a relatively side effect friendly drug. Many of the adverse effects associated with anabolic steroids will not exist with this SARM; however, some will, although mildly.
Estrogenic: The side effects of Ostarine should not include those of an estrogenic nature as the SARM does not aromatize. There is no conversion of testosterone to estrogen associated with this drug. Water retention, bloating, gynecomastia or high blood pressure due to water retention cannot occur. However, data shows that some increases in existing estrogen may occur, but should be very mild and not enough to warrant the use of an anti-estrogen. If this very slight increase is concerning, if an anti-estrogen is used, you may easily bottom out your estrogen levels, which can lead to numerous hormone imbalances and related effects.
Androgenic: Androgenic side effects of Ostarine, despite directly affecting the androgen receptor should not exist. This compound does not convert to DHT; acne and hair loss cannot occur. Androgenic side effects associated with virilization in women are also impossible. As there is no direct androgenic activity related to DHT, prostate issues should also be non-existent.
Cardiovascular: The side effects of Ostarine should present minimal cardiovascular risk. Both HDL and LDL levels may be reduced, but all data shows minimal to insignificant reductions.
Testosterone Suppression: It’s often said SARM’s will not suppress natural testosterone production, and it’s true they will not compared to anabolic steroids. However, some suppression is possible, but complete suppression is not. A testosterone-boosting supplement may be warranted while using MK 2866. Post Cycle Therapy (PCT) data is somewhat inconclusive as to if this is needed. Some men seem to experience greater levels of testosterone suppression than others.
Hepatotoxicity: Although orally administered, the side effects of Ostarine do not include liver toxicity. MK 2866 does not belong to the C17-alpha alkylated (C17-aa) class of drugs like many oral anabolic steroids. It does not mirror the MI metabolite associated with the SARM S4 that gives that particular SARM some hepatic activity.